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Abstract
Background: Matrix metalloproteinases (MMP) have been shown to play a role in colorectal cancer (CRC).
More recently, MMP1, MMP3 and MMP7 functional gene promoter polymorphisms have been found to be
associated with CRC occurrence and prognosis. To document the role of MMP polymorphisms in the early step
of colorectal carcinogenesis, we investigated their association with colorectal adenoma risk in a case-control
study comprising 295 patients with large adenomas (LA), 302 patients with small adenomas (SA) and 568 polyp-
free (PF) controls.
Methods: Patients were genotyped using automated fragment analysis for MMP1 -1607 ins/del G and MMP3 -
1612 ins/delA (MMP3.1) polymorphisms and allelic discrimination assay for MMP3 -709 A/G (MMP3.2) and MMP7
-181 A/G polymorphisms. Association between MMP genotypes and colorectal adenomas was first tested for each
polymorphism separately and then for combined genotypes using the combination test. Adjustment on relevant
variables and estimation of odds ratios were performed using unconditional logistic regression.
Results: No association was observed between the polymorphisms and LA when compared to PF or SA. When
comparing SA to PF controls, analysis revealed a significant association between MMP3  -1612 ins/delA
polymorphism and SA with an increased risk associated with the 6A/6A genotype (OR = 1.67, 95%CI: 1.20–2.34).
Using the combination test, the best association was found for MMP3.1-MMP1 (p = 0.001) with an OR of 1.88
(95%CI: 1.08–3.28) for the combined genotype 2G/2G-6A/6A estimated by logistic regression.
Conclusion: These data show a relation between MMP1 -1607 ins/del G and MMP3 -1612 ins/delA combined
polymorphisms and risk of SA, suggesting their potential role in the early steps of colorectal carcinogenesis.
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Background
Colorectal cancer (CRC) is one of the most common
human malignancies with more than 300,000 cases both
in the United States and in the European Union each year.
The majority of the cases are sporadic and develop from a
pre-malignant lesion, the adenomatous polyp [1]. Colon-
oscopic polypectomy has been proved to reduce signifi-
cantly the incidence of colorectal cancer [2,3]. Therefore,
the identification of factors associated with the develop-
ment of colorectal adenoma represents a major goal in the
prevention of colorectal cancer. Indeed, they could allow
the selection of individuals at risk of CRC who may bene-
fit from a screening by colonoscopy.
Matrix metalloproteinases (MMPs) are an important fam-
ily of metal-dependant enzymes that are responsible for
the degradation of extracellular matrix components.
MMPs are involved in various physiologic processes, such
as embryogenesis and tissue remodeling [4,5]. They also
play a key role in invasion and metastasis of tumor cells
which require proteolysis of basal membranes and extra-
cellular matrix [6]. For a long time, MMPs were consid-
ered to be important almost exclusively in these two steps
of carcinogenesis. However, recent studies suggested that
MMPs are involved in several other processes associated
with cancer development. Indeed, they regulate tumor
growth and apoptosis, they promote angiogenesis, loss of
cell adhesion, invasion and metastasis. Finally, some of
them are also required in immune responses to cancer [7].
The role of MMPs in CRC has been described [8,9].
Numerous, including MMP1, MMP3 and MMP7 are over-
expressed in colorectal tumors [10,11]. The expression of
MMP7 was shown to correlate with Dukes' stage and
increased metastatic potential [12,13] while MMP-1
expression was shown to be related to invasion, metastasis
and prognosis [14-16]. Moran et al. demonstrated that
MMP3 expression was significantly lower in CRC with
high microsatellite instability which are known to have a
better clinical outcome than CRC without microsatellite
instability [17]. This observation suggests that MMP3
could be implicated in tumor invasion, lymph node
involvement and metastatic spread in CRC. MMPs are
overexpressed in a variety of premalignant tumor tissues,
including colorectal adenoma [18-20] and MMP7 has
been shown to be important in the growth of early colonic
adenomas and their transformation into invasive cancer
[21].
A functional single nucleotide polymorphism (SNP) has
been reported in the MMP1 gene promoter that consists in
a guanosine (G) insertion at position -1607. This SNP
generates a new 5'-GGA-3' core recognition sequence for
members of the Ets family of transcription factors [22]. In
vitro, the homozygous 2G/2G genotype results in an
increased transcription activity compared to the 1G/1G
genotype. In vivo, an association was found between the
2G allele and MMP1 overexpression in ovarian cancer tis-
sue [23]. The MMP1 2G/2G genotype was reported to be
linked to an increased risk of CRC [24,25]. Indeed, the 2G
allele was shown to favor invasion, metastasis and prog-
nosis [25,26]. A SNP corresponding to an insertion/dele-
tion of an adenosine (A) at position -1612 of the MMP3
gene promoter was also described and shown to interfere
with transcriptional activity [10]. In a case-control study,
Hinoda et al. found that the frequency of the 6A allele was
significantly higher in CRC patients than in controls, as
the frequency of the 6A/6A genotype compared to the 5A/
6A + 5A/5A genotypes [24]. In this study, MMP1  and
MMP3 were in significant linkage desequilibrum and the
most frequent haplotype 2G-6A was significantly
increased in CRC patients compared to controls. Concern-
ing the other MMP3 polymorphisms, four are in substan-
tial linkage desequilibrum with the -1612 ins/del A (-
1986 T/C, -1346 A/C, -376 G/C, and +802 A/G), except
one (-709 A/G) which is not of proven functional impor-
tance [27]. In the MMP7 gene promoter region, two SNPs
(-181 A/G and -153 C/T) have been shown to modify the
gene transcription activity [28]. Recently, both SNPs have
been associated with CRC susceptibility and the -181 G/G
genotype was linked to distant metastasis [29]. These find-
ings are in favor of the role of MMP1, MMP3 and MMP7
functional gene polymorphisms in colorectal carcinogen-
esis. They are localized in a MMP cluster of 400 kb at
11q21–23 that counts 9 MMPs (MMP-1, 3, 7, 8, 10, 12,
13, 20, 27).
To explore whether MMP1, MMP3 and MMP7 gene pro-
moter polymorphisms are involved in the early step of
colorectal carcinogenesis, we investigated the relation
between these polymorphisms and the risk of colorectal
adenoma in a case-control study.
Methods
Selection of cases and controls
The GEADE study is a case-control and family study of
patients with high-risk adenomas (larger than 9 mm). The
data were obtained from 18 participating gastroenterol-
ogy units of general hospitals in France (table 3). From
September 1995 to March 2000, 306 consecutive patients
with newly diagnosed colorectal large adenoma (LA) were
enrolled in the study. Subjects with history of cancer,
familial adenomatous polyposis, established hereditary
non-polyposis colorectal cancer and inflammatory bowel
disease had been excluded. In order to be able to distin-
guish genetic factors involved in the occurrence of adeno-
mas or in their growth, 307 cases with small adenomas
(SA) (smaller than 0.5 cm) and 572 polyp-free (PF) con-
trols (with normal colonoscopy) were enrolled in the
same units. All patients and controls were Caucasian.BMC Cancer 2006, 6:270 http://www.biomedcentral.com/1471-2407/6/270
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Information on indication of colonoscopy, family history
of CRC, and completeness of colonoscopy was also col-
lected for all patients and controls. Controls (2 per case)
were matched to LA cases by age, gender, and geographic
area (five regions: Paris area, North-East, Centre, South-
West and South-East, France) (table 3). Patients with SA
were relatively rare and could not be matched with LA
cases. Blood specimens were obtained at the time of the
colonoscopy and were kept only if adenoma was diag-
nosed after histological examination (for LA and SA
cases). Twenty individuals could not be genotyped
because biological material was not sufficient: 11 cases
with LA, 5 cases with SA and 4 PF controls. The final sam-
ple was thus: 295 cases with LA, 302 cases with SA and
568 PF controls. A complete description of the patients
sample is given in Cottet et al. [30]. All patients and con-
trols gave their informed consent and the study was
approved by an ethics committee for biomedical research
(Le Kremlin-Bicêtre) and by the National Committee
CNIL (Commission nationale de l'informatique et des lib-
ertés).
MMP1, MMP3 and MMP7 genotyping
The  MMP1  -1607 ins/del G, MMP3  -1612 ins/del A,
MMP3 -709 A/G and MMP7 -181 A/G polymorphisms
were named respectively MMP1, MMP3.1, MMP3.2 and
MMP7  polymorphisms.MMP1  and  MMP3.1  have been
studied by genotyping lymphocyte DNA by multiplex
PCR-based approach using the following primers: 5'
[6FAM]-GCCCTCTTGAACTCACATGTTATG-3' and 5'-
ACTTTCCTCCCCTTATGGATTCC-3' for MMP1, 5'-GTC-
CTCATATCAATGTGGCCAAA-3' and 5' [6FAM]-
CGGCACCTGGCCTAAAGAC-3' for MMP3.1  polymor-
phism as previously described [31]. After amplification
and dilution, fragments were separated on a ABI Prism
3700 DNA Genetic Analyzer (Applied Biosystems).
The MMP3.2 and MMP7 polymorphisms were studied by
real-time PCR allelic discrimination assay on ABI 7900 HT
Sequence Detection System (Applied Biosystems) as pre-
viously described [31]. For the MMP7 DNA amplification
was performed with forward 5'-AGTCAATTTATGCAGCA-
GACAGAAA-3' and reverse 5'-GTGTTATTTTTCAT-
TAACTAAAACGAGGA-3' primers and allelic
discrimination was performed by the use of specific
probes for each allele respectively labelled with fluores-
cent reporter dyes VIC and FAM: 5'ACAATGTATTT-
GTCTTTC-3' and 5'-CAATGTATTCGTCTTTC-3'. For the
MMP3.2 polymorphism, a mix containing specific prim-
ers and fluorescent probes designed by Applied Biosys-
tems (Taqman SNP Genotyping Assay, ID
C_3047714_10) was used. Some QC blinded samples
were distributed throughout the runs and genotyped for
concordance of results and control samples without DNA
samples were systematically included in each MMP geno-
typing plate.
Statistical analysis
Hardy-Weinberg proportions were tested for each poly-
morphism. Linkage disequilibrium (LD) between pair-
wise loci was estimated using the measure D' [32].
Association was first tested for each polymorphism sepa-
rately. For each polymorphism, genotype-specific odds
ratio (OR) and 95% confidence intervals (CI) were com-
puted using unconditional logistic regression adjusted on
matching factors and Wald test was used to assess the glo-
bal effect of this SNP. The homozygous genotype for the
more frequent allele among controls was set as the refer-
ence class. Homogeneity of allele frequencies within
regions was previously tested. Tests of homogeneity and
unconditional logistic regression were done using STATA.
The association was further examined using the combina-
tion test, a method developed by Jannot et al. [33] that
allows for the analysis of all possible combinations of 1 to
n tightly linked SNPs in order to test their association with
the disease. For each SNP combination, the method com-
putes a statistic test contrasting the genotypic (or haplo-
typic) distribution between cases and controls. Because all
these tests are correlated (many of them are nested in each
others, and the SNPs are likely to be in LD), a permutation
procedure is implemented which displays a significance
level adequately adjusted for multiple testing. In a second
step, among the significantly associated combinations,
the most parsimonious one can be identified by compar-
ing nested combinations using chi2 tests.
With the 4 SNPs of the present study, a total of 15 SNP
combination were tested (4 single SNP tests, 6 two-SNP
tests, 4 three-SNP tests and 1 four-SNP test).
Table 1: Characteristics of the study population
Large adenomas Small adenomas Polyp free controls
N 295 302 568
Age, mean (SD) 62.3 (13.1) 60.6 (12.1) 60.7 (12.4)
Sex ratio (male/female) 1.68 1.24 1.52
SD; standard deviationBMC Cancer 2006, 6:270 http://www.biomedcentral.com/1471-2407/6/270
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First, we used the FAMHAP12 software to apply this
method by performing haplotypic tests [34]. Then, the
COMBINTEST (Jannot, personal communication) was
used to perform genotypic tests.
As the combination test does not yet allow an adjustment
on confounders, when association was found significant,
the combination was further tested using unconditional
logistic regression and the risks associated with the differ-
ent genotypes were estimated.
Results
Table 1 shows some characteristics of the cases and con-
trols. LA cases were slightly older than SA and PF controls,
but there was no age difference between LA and SA
patients, despite the absence of matching. The sex ratio
(male/female) was similar in LA and PF because of match-
ing, and slightly higher in LA than in SA patients.
The distribution of genotypes for the 4 polymorphisms
was consistent with Hardy-Weinberg equilibrium (p =
0.65 for MMP1, p = 0.13 for MMP3.1, p = 0.36 for
MMP3.2 and p = 0.10 for MMP7). As shown in table 2,
three of the four polymorphisms (MMP1, MMP3.1 and
MMP3.2) were in LD but MMP7 was only in slight LD
with MMP3.2 polymorphism (D' = 0.18) and was not
found in LD with the other ones (D'< 0.05).
Some differences in allele frequencies were found
between centres inside the regions defined for matching
(the homogeneity of allele frequencies was rejected for 5
tests among the 20 ones performed). Although such dif-
ferences might be due to chance, there might exist some
kind of stratification within the 5 regions initially defined,
as found for other polymorphisms [35]. Therefore, we
adjusted analyses on smaller groups of centres to protect
against spurious association due to possible remaining
population admixture. Centres with too few participants
were pooled with the geographically closest ones, which
led to eleven categories (table 3).
Results of analyses by single polymorphisms for LA vs PF,
LA vs SA and SA vs PF are presented in table 4. No associ-
ation was observed between the polymorphisms and LA
when compared to PF or SA. Conversely, a significant
effect of MMP3.1 polymorphism was found when com-
paring SA to PF controls (p = 0.008, Wald test). The data
suggest an opposite effect of 6A allele depending on
whether one or two copies were present. Compared with
the 5A/5A genotype, the 6A/6A variant genotype appeared
associated with an increased risk of SA whereas 5A/6A was
inversely associated but the ORs were not significantly dif-
ferent from 1.0. When we considered a recessive model,
the genotype 6A/6A was this time clearly associated with
a higher risk of SA compared with the genotypes 5A/5A
and 5A/6A pooled together (OR = 1.67, 95%CI: 1.20–
2.34).
The haplotypic analysis with the combination test did not
reveal any effect of the 4 polymorphisms on LA. When
comparing SA vs PF, the test was globally significant after
correction for multiple testing (p = 0.012). The combina-
tion of polymorphisms found associated with SA with the
lowest p-value was MMP1-MMP3.1 (p = 0.001, uncor-
rected). This was the best combination as no other combi-
nations of 1 or 2 SNP was significantly associated with SA
(in particular, when MMP3.1 was considered alone, the p-
value was 0.059). The genotypic analysis by the combina-
tion test provided quite similar results with a p-value of
0.03 after correction for multiple testing. The lowest p-
value was found for the same combination MMP1-
MMP3.1 (p = 0.003, uncorrected). The only difference was
that MMP3.1 SNP alone was significantly associated with
SA (p = 0.011). As in the haplotypic analysis, the compar-
ison between statistics of MMP1-MMP3.1 and MMP3.1
combinations showed that the combination MMP3.1-
MMP1 was the most significantly associated one.
An association between combined MMP1-MMP3.1 geno-
types and SA was confirmed by logistic regression
adjusted on centre (p = 0.002) (table 5). The same oppo-
site effect of 5A and 6A alleles shown in the SNP by SNP
analyses was found for MMP3.1 but only for the carriers
of genotype 2G/2G at the MMP1 locus.
Discussion
We investigated the role of MMP1, MMP3 and MMP7 pro-
moter polymorphisms as colorectal cancer risk factors in
a case-control study of cases with large adenomatous pol-
yps (n = 295), versus small adenomatous polyps cases (n
= 302) or PF controls (n = 568). These polymorphisms are
known to modulate transcriptional activity, except for one
(MMP3 -709 A/G) that is not of proven functional impor-
tance [27].
Table 2: Linkage disequilibrium (D') between pairwise polymorphisms
Polymorphisms D' (p-value) MMP3.1 MMP7 MMP3.2
MMP1 0.429 (< 0.001) 0.016 (0.686) 0.761 (< 0.001)
MMP3.1 0.040 (0.231) 0.946 (< 0.001)
MMP7 0.185 (0.005)BMC Cancer 2006, 6:270 http://www.biomedcentral.com/1471-2407/6/270
Page 5 of 8
(page number not for citation purposes)
The distribution of genotypes for the four polymorphisms
was consistent with Hardy-Weinberg equilibrium. MMP1,
MMP3.1 and MMP3.2 polymorphisms were found in LD,
as previously in several studies, the MMP1  2G and
MMP3.1 6A alleles as well as the MMP1 1G and MMP3.1
5A alleles were in LD with a D' coefficient between 0.50
and 0.92 according to the ethnic origin of the patients
[24,26,31]. Concerning the MMP3.2 -709 A/G polymor-
phism, few data are available but one study reported a
substantial LD between five MMP3 promoter polymor-
phisms, except for this one, which had a lower frequency
of the minor allele (0.2 vs > 0.4 for the minor allele of the
other polymorphisms) [27]. The MMP7 polymorphism
was not found in LD with the others (D' < 0.05), which is
consistent with the literature [31].
In this case-control study, the MMP3.1 6A/6A genotype
was significantly associated with an increased risk of SA
when compared to PF controls (OR = 1.67, 95%CI: 1.20–
2.34, under a recessive model) while no association was
observed between the MMP polymorphisms analyzed and
LA when compared to PF or SA. Moreover, the combina-
tion test revealed a stronger effect of the MMP1-MMP3.1
2G/2G-6A/6A combined genotype. These results suggest
that MMP1 polymorphism, which was not found to influ-
ence adenoma risk when taken alone, may have a role by
interacting with the effect of MMP3.1. This finding under-
lines the importance of using the combination test for
demonstrating combined effects of polymorphisms with
little or no individual effect. Indeed, this test has been
shown to be particularly powerful to detect the effect of
polymorphisms when several polymorphisms interact
with low marginal effect of each SNP and when one of the
SNPs masks the expression of the other ones [33]
Our data suggest that the MMP3.1 polymorphism, and
especially the MMP1-MMP3.1  2G/2G-6A/6A combined
genotype might play a role at the earliest step of colorectal
carcinogenesis by promoting the development of adeno-
mas from normal colon epithelial cells. However, the fol-
lowing steps of colorectal carcinogenesis, in particular
adenoma growth, could require the contribution of other
factors. These factors could mask the effect of MMP1-
MMP3.1 combined genotype and explain the absence of
association when LA patients are compared to PF controls.
However, these preliminary results must be taken with
caution and have to be confirmed.
The MMP3.1 6A/6A genotype has already linked to the
development of CRC. Indeed, its frequency was signifi-
cantly higher in CRC patients than in controls when com-
pared to the 5A/5A + 5A/6A genotypes in a case-control
study [24]. These results are inconsistent with the hypoth-
esis that the increased transcriptional level of MMP3
increases CRC susceptibility as the 6A/6A genotype is
associated with the lowest transcriptional level [36]. One
Table 3: Distribution of cases and controls in the different centres and groups of centres
Region Centre Number of individuals by centre Number of individuals by group of centres
All cases Controls All cases Controls
Paris area Le Chesnay 10 15
M e a u x 4 53 25 54 7
Orleans 16 7
Le Mans 49 49 65 56
D r e u x 1 23 91 23 9
North-East Evreux 25 16
Beauvais 8 19
Soissons 1 1
C o m p i è g n e 2 41 65 85 1
Metz 45 49 45 49
Centre Vichy 38 2
Bourg en Bresse 76 51 114 53
Beaune 37 37 37 37
South-West Tarbes 31 29 31 29
P a u 6 75 46 75 4
South-East Toulon 10 10
Aix en Provence 58 61 68 71
Montélimar 45 36 45 36BMC Cancer 2006, 6:270 http://www.biomedcentral.com/1471-2407/6/270
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explanation may be that MMP3 is indirectly involved in
the development of CRC [24]. The presence of an
increased risk of adenomatous polyps of the colon in cor-
onary atherosclerosis patients [37,38] suggested that the
association of the MMP3 6A/6A genotype and CRC is due
to its link with an increased atherosclerosis risk [39-41].
These speculations should obviously be taken with cau-
tion and the mechanisms underlying the potential
involvement of MMP3.1 polymorphism in colorectal car-
cinogenesis remain to be clearly determined.
Different studies showed that some MMP, including
MMP2, MMP7 and MMP9 are expressed in colorectal ade-
nomas that are well established premalignant lesions of
colorectal cancers [18-20,42], implying their role other
than extracellular matrix destruction and metastasis in
cancer development and progression. The expression of
E1AF, an Ets family transcriptional factor that plays a role
in the progression of CRC, has been shown to be associ-
ated with the expression of MMP1 and MMP7 in CRC tis-
sues [43,44]. Moreover, E1AF has been reported to be a
potent activator of cyclooxygenase-2 (COX-2) transcrip-
tion [45] and it is established that COX-2 plays an impor-
tant role in the early stages of colorectal carcinogenesis
[46]. Finally, absence of MMP7 may result in a significant
reduction in mean tumour number and average tumour
diameter in Min (multiple intestinal neoplasia) mice defi-
cient in this MMP [21]. These findings suggest that some
MMP might contribute to early tumour development,
especially in tumours of gastrointestinal tract. Although
several studies analyzed the expression of different MMP
in colorectal adenomas, none had investigated the role of
functional MMP polymorphisms in the development of
these premalignant lesions despite evidence of their
implication in colorectal carcinogenesis.
In the present study, the MMP3.1 6A/6A genotype was sig-
nificantly associated with an increased risk of SA. Moreo-
ver, the analysis of the effects of combined MMP
genotypes by the means of the combination test allowed
to find an indirect role of MMP1 polymorphism in this
early step of colorectal carcinogenesis since a potentialisa-
tion of the effect of MMP3.1 polymorphism by this poly-
morphism has been shown. Such an effect would not have
been identified if a separated analysis of each MMP geno-
type had been performed, underlining the relevance of the
combination test.
Conclusion
These data show a relation between MMP1  -1607 ins/
delG and MMP3  -1612 ins/delA combined polymor-
phisms and risk of colorectal SA, suggesting their poten-
tial role in the early steps of colorectal carcinogenesis.
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Table 4: Association between genotypes of MMP and colorectal adenomas
Large adenoma patients 
(LA)
Polyp free controls 
(PF)
Small adenoma patients 
(SA)
LA vs PF LA vs SA SA vs PF
OR* (95%CI) P** OR* (95%CI) P** OR* (95%CI) P**
MMP1
1G/1G 81 154 81 1 1 1
1G/2G 139 285 139 0.94 (0.66–1.33) 1.04 (0.69–1.56) 0.96 (0.67–1.37)
2G/2G 72 122 79 1.18 (0.78–1.78) 0.491 0.90 (0.56–1.43) 0.792 1.22 (0.81–1.84) 0.431
MMP3.1
5A/5A 70 130 68 1 1 1
5A/6A 139 291 132 0.87 (0.60–1.25) 1.10 (0.72–1.69) 0.85 (0.58–1.24)
6A/6A 73 126 93 1.11 (0.73–1.69) 0.391 0.78 (0.48–1.25) 0.250 1.50 (0.99–2.28) 0.008
MMP3.2
AA 182 358 194 1 1 1
AG 105 187 92 1.10 (0.81–1.50) 1.20 (0.83–1.73) 0.87 (0.64–1.20)
GG 7 19 16 0.72 (0.29–1.78) 0.615 0.49 (0.19–1.27) 0.175 1.34 (0.65–2.75) 0.464
MMP7
AA 92 187 99 1 1 1
AG 138 259 136 1.08 (0.77–1.50) 1.06 (0.72–1.56) 0.98 (0.70–1.38)
GG 64 119 67 1.17 (0.78–1.77) 0.742 1.08 (0.67–1.72) 0.944 1.14 (0.76–1.71) 0.746
* OR adjusted on age, sex, and group of centres
** P: p-value for the Wald test assessing the global effect of SNP, uncorrected for multiple testingBMC Cancer 2006, 6:270 http://www.biomedcentral.com/1471-2407/6/270
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